367 related articles for article (PubMed ID: 30664361)
1. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
3. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
5. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
6. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
Lin BW; Huang WL; Wang L; Chen ZM
J Ocul Pharmacol Ther; 2018 Nov; 34(9):633-641. PubMed ID: 30227093
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
Bang SP; Yeon CY; Adhikari N; Neupane S; Kim H; Lee DC; Son MJ; Lee HG; Kim JY; Jun JH
PLoS One; 2019; 14(11):e0224805. PubMed ID: 31738791
[TBL] [Abstract][Full Text] [Related]
9. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model.
Kim CE; Kim YJ; Hwang MW; Park YJ; Yang J
Biomed Pharmacother; 2021 Jul; 139():111571. PubMed ID: 33857915
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
11. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
12. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
Hongyok T; Chae JJ; Shin YJ; Na D; Li L; Chuck RS
Arch Ophthalmol; 2009 Apr; 127(4):525-32. PubMed ID: 19365035
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
14. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the mineral oil and hyaluronic acid mixture eye drops in murine dry eye.
Choi JH; Kim JH; Li Z; Oh HJ; Ahn KY; Yoon KC
Korean J Ophthalmol; 2015 Apr; 29(2):131-7. PubMed ID: 25829831
[TBL] [Abstract][Full Text] [Related]
17. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
[TBL] [Abstract][Full Text] [Related]
18. Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.
Jiao X; Qi Y; Gao N; Zhang C; Zhao S; Yang R
Eye (Lond); 2024 Apr; 38(5):937-944. PubMed ID: 37904000
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.
Turner K; Pflugfelder SC; Ji Z; Feuer WJ; Stern M; Reis BL
Cornea; 2000 Jul; 19(4):492-6. PubMed ID: 10928765
[TBL] [Abstract][Full Text] [Related]
20. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
Hom MM
Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]